抗纤维化治疗特发性肺纤维化患者生存的血浆生物标志物
基于这些标志物构建的临床-分子特征可预测抗纤维化治疗患者的预后风险。
要点
- 抗纤维化治疗患者中,CA-125、CXCL13、MMP7、YKL-40和OPN预测无移植生存的阈值高于未暴露者。
- 抗纤维化暴露患者血浆生物标志物水平随时间保持稳定,而未暴露者一般升高。
- 临床-分子特征在抗纤维化暴露患者中预测无移植生存风险(HR 5.91,95%CI 2.25-15.5),并在独立队列中验证(HR 3.97,95%CI 1.62-9.72)。
核心结论
- 多数血浆生物标志物在抗纤维化治疗IPF患者中仍可预测无移植生存,但阈值高于未治疗者。
- 基于生物标志物的临床-分子特征可能可靠预测抗纤维化治疗患者的预后风险,但需进一步优化和验证。
研究设计与样本
- 使用迭代Cox回归确定各组生物标志物最佳二分阈值,线性混合回归评估纵向变化,并在独立IPF队列中验证临床-分子特征。
主要发现
- CA-125、CXCL13、MMP7、YKL-40和OPN在抗纤维化暴露患者中预测无移植生存差异,但阈值高于未暴露个体。
- 未暴露患者血浆生物标志物水平随时间一般升高,而抗纤维化暴露患者保持不变。
- 临床-分子特征预测抗纤维化暴露患者无移植生存降低(HR 5.91;95%CI 2.25-15.5;P < .001),独立队列中保持关联(HR 3.97;95%CI 1.62-9.72;P = .003)。
临床怎么用
- 在抗纤维化治疗IPF患者中解读血浆生物标志物时需考虑更高阈值。
- 临床-分子特征可用于辅助评估抗纤维化治疗患者的预后风险,但尚需进一步研究优化和验证。
局限性
- 临床-分子特征需要额外研究进行优化和验证。
- 纵向生物标志物变化仅在部分患者亚组中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A number of circulating plasma biomarkers have been shown to predict survival in patients with idiopathic pulmonary fibrosis (IPF), but most were identified before the use of antifibrotic (AF) therapy in this population. Because pirfenidone and nintedanib have been shown to slow IPF progression and may prolong survival, the role of such biomarkers in AF-treated patients is unclear. RESEARCH QUESTION: To determine whether plasma concentration of cancer antigen 125 (CA-125), C-X-C motif chemokine 13 (CXCL13), matrix metalloproteinase 7 (MMP7), surfactant protein D (SP-D), chitinase-3-like protein-1 (YKL-40), vascular cell adhesion protein-1 (VCAM-1), and osteopontin (OPN) is associated with differential transplant-free survival (TFS) in AF-exposed and nonexposed patients with IPF. STUDY DESIGN AND METHODS: A pooled, multicenter, propensity-matched analysis of IPF patients with and without AF exposure was performed. Optimal thresholds for biomarker dichotomization were identified in each group using iterative Cox regression. Longitudinal biomarker change was assessed in a subset of patients using linear mixed regression modeling. A clinical-molecular signature of IPF TFS was then derived and validated in an independent IPF cohort. RESULTS: Three hundred twenty-five patients were assessed, of which 68 AF-exposed and 172 nonexposed patients were included after propensity matching. CA-125, CXCL13, MMP7, YKL-40, and OPN predicted differential TFS in AF-exposed patients but at higher thresholds than in AF-nonexposed individuals. Plasma biomarker level generally increased over time in nonexposed patients but remained unchanged in AF-exposed patients. A clinical-molecular signature predicted decreased TFS in AF-exposed patients (hazard ratio [HR], 5.91; 95% CI, 2.25-15.5; P < .001) and maintained this association in an independent AF-exposed cohort (HR, 3.97; 95% CI, 1.62-9.72; P = .003). INTERPRETATION: Most plasma biomarkers assessed predicted differential TFS in AF-exposed patients with IPF, but at higher thresholds than in nonexposed patients. A clinical-molecular signature of IPF TFS may provide a reliable predictor of outcome risk in AF-treated patients but requires additional research for optimization and validation.
引用
- Adegunsoye A, Alqalyoobi S, Linderholm A, et al. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020. PMID: 32450241. doi:10.1016/j.chest.2020.04.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。